Aurinia Pharmaceuticals sees strong Q4 revenue growth, eyes cash flow positivity
AUPH Stock | USD 9.20 0.05 0.54% |
Under 55% of Aurinia Pharmaceuticals' investor base is interested to short. The analysis of the overall investor sentiment regarding Aurinia Pharmaceuticals suggests that many traders are impartial. Aurinia Pharmaceuticals' investing sentiment shows overall attitude of investors towards Aurinia Pharmaceuticals.
Aurinia |
Aurinia Pharmaceuticals has reported prelim net revenue of 45M for fourth quarter compared to consensus estimate of 44.20M and highlighting a 49 percent increase for the fourth quarter..
Read at seekingalpha.com
Aurinia Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Aurinia Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Aurinia Pharmaceuticals Fundamental Analysis
We analyze Aurinia Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aurinia Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aurinia Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
Aurinia Pharmaceuticals is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Aurinia Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aurinia Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aurinia Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aurinia Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Aurinia Pharmaceuticals Related Equities
BTAI | BioXcel Therapeutics | 5.41 | ||||
MDGL | Madrigal Pharmaceuticals | 0.30 | ||||
EXEL | Exelixis | 0.65 | ||||
PTCT | PTC Therapeutics | 1.33 | ||||
AXSM | Axsome Therapeutics | 1.44 | ||||
SRPT | Sarepta Therapeutics | 1.52 | ||||
TERN | Terns Pharmaceuticals | 1.87 | ||||
AKRO | Akero Therapeutics | 2.22 | ||||
TGTX | TG Therapeutics | 2.90 | ||||
MCRB | Seres Therapeutics | 3.26 | ||||
VKTX | Viking Therapeutics | 3.56 | ||||
HEPA | Hepion Pharmaceuticals | 8.00 |
Complementary Tools for Aurinia Stock analysis
When running Aurinia Pharmaceuticals' price analysis, check to measure Aurinia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurinia Pharmaceuticals is operating at the current time. Most of Aurinia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aurinia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurinia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aurinia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |